Bliss GVS Pharma share news, announcements and annual reports
NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap
Bliss GVS Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹647.50down ₹33.40 (4.91%)BSE ₹648.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹680.90.
30 Oct: open ₹660.00, high ₹670.00, low ₹646.90
52-week range of traded prices to 30 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,885 Cr1,000th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.71
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.23%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,45,760
Bliss GVS Pharma share news and announcements
628 announcements, routine notices left out, newest first. Page 13 of 13.
Mar 2011
9 Mar · Updates
Name of Share Transfer Agent of the Company has been changed from Mondkar Computers Pvt. Ltd. to Universal Capital Securities Pvt. Ltd.8 Mar · Purchase of Shares
3 Mar · Purchase of Shares
Feb 2011
2 Feb · Board meeting
Board of Directors of the Company at their meeting held on February 02, 2011 has approved the following : (1) Resignation of Mr. Mahendra N. Thakkar from the Directorship of the Company; (2) Appointment of Mr. Yogendra N. Thakkar as Independent Director of the Company.
Jan 2011
25 Jan · Board meeting
To consider, interalia, the Un-audited Financial Results for the Quarter ended December 31, 2010.
Nov 2010
11 Nov · Corporate action
Board of Directors of the Company have fixed November 27, 2010 as the Record Date for the payment of Interim Dividend.11 Nov · Address Change
Company has decided to change its registered office from 6/29A, Udit Mittal Industry, Andheri Kurla Road, Andheri (East), Mumbai 400059 to 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai 400 072 w.e.f. December 25, 2010.11 Nov · Dividend
Board of Directors of the Company at its meeting held on November 11, 2010 have recommended an Interim Dividend of 30% i.e. Rs.0.30 per Equity Share for the year 2010-2011.3 Nov · Board meeting
To consider, interalia, the Un-audited Financial Results for the Quarter ended September 30, 2010 & Dividend if any.
Oct 2010
29 Oct · Purchase of Shares
Vide its letter dated October 28, 2010 that Mr. Gautam R. Ashra has purchased 31,000 equity Shares of the Company from Genteel Trading Co. Pvt. Ltd. at an average rate of Rs. 40.19 per share.
Sep 2010
6 Sep · Updates
Mr. S.N. Kamath Promoter & Managing Director of the Company has received a " National Award-2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises".3 Sep · Purchase of Shares
Vide its letter dated August 30, 2010 that Mrs. Prabhavati R. Ashra Mother of Mr. Gautam R. Ashra- Promoter Director of the Company today purchase of 50000 equity Shares of the Company for average purchase price of Rs. 38.82 per share at the BSE.
Aug 2010
5 Aug · Updates
The company has signed a Joint Venture Agreement with Kuwait Saudi Pharmaceutical Industries Co. at Kuwait for establishing a Suppository Line Manufacturing Facility in Kuwait3 Aug · Meeting
Meeting of the Shareholders of the Company held on August 03, 2010 : (1) Approved and adopted Profit and Loss Account for the year ended March 31, 2010, Balance Sheet as at that day and the Reports of Directors and Auditors thereon; (2) Appointed Mr. Gautam R Ashra who retires by rotation and eligible offers himself for re-appointment; (3) Reappointed M/s B.K. Khare & Co as auditors of the Company; (4) Declared dividend @ 50% per share; (5) Appointed Dr. Vibha N. Kamath as Whole time Director of the Company; (6) Re-appointed and revised salary of Mr. S. N. Kamath as Managing Director of the Company; and (7) Re-appointed and revised salary of Miss Shruti N. Kamath as Wholetime Director of the Company.
Jul 2010
30 Jul · Management
Board of Directors of the Company at its meeting held on July 28, 2010 has approved: (1) Subject to section 314 of the Companies Act 1956 Mr.Gagan Harsh Sharma appointed as General Manager of the Company relative of Mr. S.N. Kamath-Promoter & Managing Director of the Company.